Through expanding our knowledge of the human commensal virome, our revolutionary platform can exploit unique properties and tissue tropisms to build vector conjugate medicines that can deliver diverse therapeutic modalities to a wide array of tissues.
Key Features
Redosable
Current vector technologies face a major barrier: the inability to repeatedly dose. The generation of antibodies against treatment results in a robust immune response to any subsequent exposure. Our vectors are comprised of viruses that are ubiquitous within the human body and do not trigger any significant immune reactions. In preclinical models, our vectors can circumnavigate neutralization against payload delivery, suggesting the potential to treat patients with pre-existing immunologic barriers and/or those requiring redosing.
Controllably targeted with cellular and tissue specificity
Many tissue types are elusive to current vector technologies, limiting the types of diseases they can treat. By leveraging a combination of innate tissue tropism and a variety of validated targeting moieties, our vectors can be highly selective for target cells and achieve binding affinities comparable to antibodies. In addition, by bringing the right mechanism to the right cells, our vector conjugates achieve the combined force of cellular and mechanistic targeting.
More targets with better pharmacology
The unique features of our vector conjugates introduce a new payload paradigm: targeted intracellular pharmacology. We can match the optimal payload to the precise disease mechanism, use standard potency payloads, and achieve minimal off-cellular-target toxicity. This opens the door to a wide range of cells and tissues including blood, muscle, CNS, GI, eye and other organs.
High payload capacity and versatility
Our vector conjugate medicines have ultra-high drug capacity compared to traditional vector technologies, a feature that dramatically expands the payload options. We have demonstrated that our vectors can be engineered as Vector Drug Conjugates to carry small molecules as Vector Oligo Conjugates to carry antisense oligonucleotides or siRNAs and to carry DNA for gene therapy applications.
Highly modular & scalable manufacturing
We have reinvented vector manufacturing to match the broad therapeutic potential of our vector conjugate medicines. Our proprietary VectorBricks™ manufacturing platform is highly modular, simplifying vector production to the level of recombinant protein production. This state-of-the-art system enables low cost and scalable production that will allow us to take our vector conjugate medicines from bench to bedside.
Interested in partnering with us to build the future of targeted medicine?
Reach out to us